Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Signal Transduction and Targeted Therapy|June 27, 2024
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinomaYanni Wang, Chang Liu, Huan Chen, et al.
JAMA Network Open|July 25, 2019
Serological Markers Associated With Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract CancerZhihao Lu, Jianling Zou, Ying Hu, et al.
Signal Transduction and Targeted Therapy|August 25, 2024
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal dataZifan Chen, Yang Chen, Yu Sun, et al.
Clinical and Translational Science|November 29, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplificationJiajia Yuan, Lin Shen, Tian Shu Liu, et al.
Cancer Immunology, Immunotherapy : CII|January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trialJifang Gong, Junning Cao, Qingyuan Zhang, et al.
Eclinicalmedicine|August 18, 2025
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I studyZhengfu Fan, Jin Wang, Dan Liu, et al.
Cancer Immunology, Immunotherapy : CII|May 24, 2021
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patientsYanni Wang, Huan Chen, Xi Jiao, et al.
Targeted Oncology|September 4, 2024
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or LymphomaJifang Gong, Ye Guo, Yanqiao Zhang, et al.
Signal Transduction and Targeted Therapy|March 20, 2025
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II studyDan Liu, Jifang Gong, Jian Li, et al.
Signal Transduction and Targeted Therapy|March 14, 2025
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trialYakun Wang, Jialin Lu, Xiaoyi Chong, et al.
Pageof 10